Home » Stocks » Zoetis

Zoetis Inc. (ZTS)

Stock Price: $161.18 USD 1.69 (1.06%)
Updated Oct 21, 2020 4:04 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 76.58B
Revenue (ttm) 6.34B
Net Income (ttm) 1.62B
Shares Out 475.15M
EPS (ttm) 3.37
PE Ratio 47.83
Forward PE 39.37
Dividend $0.80
Dividend Yield 0.50%

Stock Quote

Trading Day Oct 21, 2020
Last Price $161.18
Previous Close $159.49
Change ($) 1.69
Change (%) 1.06%
Day's Open 159.50
Day's Range 159.50 - 162.13
Day's Volume 1,456,729
52-Week Range 90.14 - 168.96

More Stats

Market Cap 76.58B
Enterprise Value 81.08B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date Oct 20, 2020
Shares Outstanding 475.15M
Float 474.68M
EPS (basic) 3.40
EPS (diluted) 3.37
FCF / Share 3.06
Dividend $0.80
Dividend Yield 0.50%
Earnings Yield 2.09%
FCF Yield 1.90%
Payout Ratio 21.40%
Shares Short 3.82M
Short Ratio 2.49
Short % of Float 0.80%
Beta 0.70
PE Ratio 47.83
Forward PE 39.37
P/FCF Ratio 52.60
PS Ratio 12.08
PB Ratio 25.97
Revenue 6.34B
Operating Income 2.17B
Net Income 1.62B
Free Cash Flow 1.46B
Net Cash -4.50B
Net Cash / Share -9.46
Gross Margin 68.91%
Operating Margin 34.18%
Profit Margin 25.50%
FCF Margin 22.97%
ROA 11.78%
ROE 59.87%
ROIC 20.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (20)

Buy 11
Overweight 1
Hold 7
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$175.47*
(8.87% upside)
Low
159
Current: $161.18
High
192
Target: 175.47
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6,2605,8255,3074,8884,7654,7854,5614,3364,2333,582
Revenue Growth7.47%9.76%8.57%2.58%-0.42%4.91%5.19%2.43%18.17%-
Gross Profit4,2683,9143,5323,2223,0273,0682,8922,7732,5812,138
Operating Income2,0241,8961,7001,394669937803741430178
Net Income1,5001,428864821339583504436245110
Shares Outstanding478483490496500501500500500500
Earnings Per Share3.112.931.751.650.681.161.010.870.490.22
EPS Growth6.14%67.43%6.06%142.65%-41.38%14.85%16.09%77.55%122.73%-
Dividend Per Share0.660.500.420.380.330.290.20---
Dividend Growth30.16%20%10.53%14.46%15.28%47.69%----
Operating Cash Flow1,7951,7901,346713664626681454497254
Capital Expenditures-460-338-224-216-224-180-184-126-135-124
Free Cash Flow1,3351,4521,122497440446497328362130
Cash & Equivalents1,9341,7011,5647271,15488261031779.0063.00
Total Debt6,6116,4524,9534,4684,8683,6313,657582575711
Net Cash / Debt-4,677-4,751-3,389-3,741-3,714-2,749-3,047-265-496-648
Assets11,54510,7778,5867,6497,9136,5886,5586,2625,7115,284
Liabilities8,8378,5926,8006,1506,8225,2515,5962,2211,9751,940
Book Value2,7082,1851,7701,4871,0681,3119404,0263,7203,344
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zoetis Inc.
Country United States
Employees 10,600
CEO Kristin C. Peck

Stock Information

Ticker Symbol ZTS
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: ZTS
IPO Date February 1, 2013

Description

Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.